Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PHAT
Strong SellSinkerPhathom Pharmaceuticals, Inc. · Healthcare · United States · $743M · Avg Vol: $13M/d
COMPANY DESCRIPTION
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. Its lead product, Voquenza (vonoprazan), is a potassium-competitive acid blocker approved for certain acid-related disorders. The company's competitive position is driven by its differentiated therapeutic offerings and its strategic focus on the significant market for GI disorders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0.7M | 55.3M | 175.1M | 1502.4% | 239.7M | 316.5M | 80.8% |
| EPS | -5.05 | -3.93 | -5.29 | -3.03 | — | -1.25 | — | — |
| Shares | 41.5M | 58.0M | 68.5M | 71.4M | +72.2% | 80.9M | — | — |
| Debt | 97.1M | 139.0M | 201.9M | 211.8M | 29.7% | 552.0M | — | — |
| Equity | -74.8M | -72.8M | -253.6M | -438.2M | — | — | — | — |
| Op CF | -146.5M | -137.6M | -266.8M | -166.8M | — | -36.7M | — | — |
| Inv CF | -1.0M | -1.6M | -0.1M | -0.2M | — | — | — | — |
| Fin CF | 120.0M | 367.6M | 182.8M | -0.3M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PHAT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc.(you) | $743M | 14 | Strong Sell |
| STTK | Shattuck Labs, Inc. | $707M | 16 | Strong Sell |
| CTMX | CytomX Therapeutics, Inc. | $699M | 11 | Strong Sell |
| SGP | SpyGlass Pharma, Inc. | $884M | 14 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $698M | 11 | Strong Sell |
| ARDX | Ardelyx, Inc. | $984M | 14 | Strong Sell |
| ALT | Altimmune, Inc. | $605M | 16 | Strong Sell |
| ACHV | Achieve Life Sciences, Inc. | $834M | 19 | Strong Sell |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $701M | 7 | Strong Sell |
| RGNX | REGENXBIO Inc. | $638M | 9 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%